【导读】太龙药业控股股东筹划公司股份转让事宜，股票停牌 中国基金报记者 李智 12月1日晚间， 太龙药业 发布公告称，公司控股股东正在筹划公司股份转让事宜，可能导致 公司控制权变更。经申请，公司股票自12月2日起停牌。 筹划公司控制权变更 太龙药业股票停牌 12月1日，太龙药业发布公告称，公司控股股东郑州泰容产业投资有限公司（以下简称泰容产 投）正在筹划公司股份转让事宜，可能导致公司控制权变更。公司股票自12月2日起停牌，预 计停牌时间不超过2个交易日。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | A 股 停牌 | 2025/12/2 | | | | 太龙药业表示，停牌期间，公司将根据事项进展情况，严格按照有关法律法规的规定和要求 履行信息披露义务。上述筹划的重大事项尚存在不确定性，广大投资者需关注后续公告，并 注意投资风险。 前三季度业绩下滑 据悉，太龙药业的主要业务为药品制造和药品研发服务，具体包含药品制剂、中药饮片、药 ...

2025年1至6月份，鸿合科技的营业收入构成为：教育占比81.91%，商用及其他占比18.09%。 每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ 截至发稿，鸿合科技市值为66亿元。 每经AI快讯，鸿合科技（SZ 002955，收盘价：27.85元）12月1日晚间发布公告称，鸿合科技股份有限 公司于2025年12月1日收到安徽省瑞丞鸿图股权投资基金合伙企业（有限合伙）的通知，瑞丞鸿图协议 收购鸿达成有限公司、邢正、王京、张树江合计持有的公司约5916万股股份（占公司股份总数的25%） 事项已在中国证券登记结算有限责任公司办理完成股份过户登记手续，并取得《证券过户登记确认 书》。本次交易股份过户完成后，瑞丞鸿图持有公司约5916万股股份及对应表决权（占公司股份总数的 25%），结合《股份转让协议》中的相关安排及XING XIUQING、鸿达成、邢正、王京和张树江出具的 《关于不谋求上市公司控制权的承诺函》，瑞丞鸿图成为公司的控股股东，合肥瑞丞成为公司的间接控 股股东，公司实际控制人由XING XIUQING、邢正 ...

Core Viewpoint - ST Tianrui (SZ300165) is planning a change in control, which may lead to a shift in its major shareholder and actual controller, Liu Zhaogui, who currently holds 20.37% of the company's shares [2][3][6]. Group 1: Control Change Announcement - Liu Zhaogui, the founder and actual controller of ST Tianrui, is in the process of planning a change in the company's control, with the stock being suspended from trading starting December 1, 2023, for no more than two trading days [2]. - The transaction related to the control change is still uncertain, as no agreements have been signed, and discussions regarding the specific transaction plan are ongoing [3]. Group 2: Regulatory Issues and Penalties - ST Tianrui has been under risk warning since December 2024 due to violations related to revenue recognition, leading to a warning and fines totaling 3 million yuan for the company and additional fines for Liu Zhaogui and other executives [3][7]. - The previous attempt to change control was halted due to an investigation by the China Securities Regulatory Commission (CSRC) [4]. Group 3: Financial Performance - ST Tianrui's financial performance has been declining, with revenue dropping to 851 million yuan in 2024, only 55.2% of its 2021 revenue, and a cumulative net loss of 354 million yuan since 2021 [7]. - The company specializes in analytical testing instruments and environmental governance, with core products including spectrometers and chromatographs [7].

【导读】ST天瑞实际控制人正筹划公司控制权变更事项 中国基金报记者 卢鸰 连续四年亏损的ST天瑞又要"卖壳"了。 ST天瑞11月30日下午公告，公司当日收到控股股东、实际控制人、董事长刘召贵出具的《关于筹划公司控制权变更事项的告知函》，获悉 刘召贵正在筹划公司控制权变更相关事宜，目前各方尚未签署相关协议，拟就具体交易方案、协议等相关事项进行论证和磋商，具体情况 以各方签订的相关协议为准。 鉴于上述事项尚存在重大不确定性，根据《深圳证券交易所上市公司自律监管指引第6号——停复牌》相关规定，经ST天瑞向深圳证券交易 所申请，公司股票（股票简称：ST天瑞，股票代码：300165）自2025年12月1日（星期一）开市起停牌，预计停牌时间不超过2个交易 日。 2023年5月12日，ST天瑞控股股东、实际控制人、董事长刘召贵与广州立多虚拟现实科技合伙企业（有限合伙）签署相关股权转让协议； 同时，ST天瑞拟向特定对象发行股份。相关事项如顺利完成，李刚将成为ST天瑞实际控制人。 校对：纪元 制作：小茉 审核：木鱼 注：本文封面图由AI生成 《中国基金报》对本平台所刊载的原创内容享有著作权，未经授权禁止转载，否则将追究法律责任 ...

Core Viewpoint - ST Tianrui is undergoing a potential change in control, as announced by its controlling shareholder and chairman Liu Zhaogui, with no agreements signed yet [1] Company Overview - ST Tianrui is a high-tech enterprise with independent intellectual property, owning nine wholly-owned subsidiaries and five controlling subsidiaries, specializing in the research, production, and sales of analytical testing instruments and software [2] Financial Performance - For the first three quarters of 2025, ST Tianrui reported a revenue of 435 million yuan, a year-on-year decrease of 26.15%, and a net profit attributable to shareholders of a loss of 1.22 million yuan [2] Stock Information - As of November 28, ST Tianrui's stock price was 4.64 yuan per share, with a total market capitalization of approximately 2.3 billion yuan [3]

Core Viewpoint - ST Tianrui (300165) is undergoing a potential change in control, as announced by its chairman Liu Zhaogui, with no agreements signed yet [2][4]. Company Overview - ST Tianrui is a high-tech enterprise with independent intellectual property rights, operating nine wholly-owned subsidiaries and five controlling subsidiaries, focusing on the research, production, and sales of analytical testing instruments [4]. Financial Performance - For the first three quarters of 2025, ST Tianrui reported a revenue of 435 million yuan, a year-on-year decrease of 26.15%, and a net loss attributable to shareholders of 1.22 million yuan [5][6]. - The company's revenue for the latest reporting period was approximately 140 million yuan, reflecting a decline of 33.03% compared to the same period last year [6]. - The net profit attributable to shareholders for the same period was approximately 8.37 million yuan, an increase of 3.95% year-on-year [6]. - The basic earnings per share for the latest reporting period was 0.0169 yuan, up 4.22% from the previous year [6].

ST天瑞（300165）(300165.SZ)发布公告，公司控股股东、实际控制人刘召贵先生正在筹划公司控制权 变更相关事宜，该事项可能导致公司控股股东及实际控制人发生变更。公司股票自2025年12月1日(星期 一)开市起停牌，预计停牌时间不超过2个交易日。 ...

每经AI快讯，11月30日，ST天瑞（300165）公告称，公司控股股东、实际控制人刘召贵先生正在筹划 公司控制权变更相关事宜，该事项可能导致公司控股股东及实际控制人发生变更。为保证公平信息披 露，避免公司股价异常波动，维护广大投资者利益，经公司向深圳证券交易所申请，公司股票自2025年 12月1日(星期一)开市起停牌，预计停牌时间不超过2个交易日。 ...

Core Viewpoint - Guangdong Huafeng New Energy Technology Co., Ltd. is undergoing a change in control, with significant implications for its ownership structure and governance, as the current controlling shareholder, Tan Guoying, has signed a share transfer agreement with Chen Yun, which may lead to a change in the company's actual controller [4][10][12]. Group 1: Control Change Overview - The company has received notification from its controlling shareholder, Tan Guoying, regarding the signing of a share transfer intention agreement with Chen Yun, which may result in a change of control [3]. - The company's stock was suspended from trading on November 24, 2025, due to the uncertainty surrounding the control change, with an initial expected suspension of no more than two trading days [3]. - The stock will resume trading on December 1, 2025, following the completion of necessary approvals and procedures [7]. Group 2: Transaction Progress - On November 28, 2025, a share transfer agreement was signed, wherein Tan Guoying will transfer a total of 34,000,000 shares (16.00% of total share capital) to Chen Yun [4][12]. - The first phase of the share transfer involves 10,700,000 shares (5.04% of total share capital) at a price of 15 RMB per share, totaling 160,500,000 RMB [5][12]. - Following the initial transfer, a subsequent transfer of 23,300,000 shares will occur between November 23, 2026, and January 31, 2027, contingent upon regulatory compliance [13][16]. Group 3: Voting Rights Delegation - Tan Guoying has also signed a voting rights delegation agreement, granting Chen Yun the irrevocable right to exercise voting rights for an additional 32,100,720 shares (15.11% of total share capital) [6][17]. - This delegation will create a concerted action relationship between Tan Guoying and Chen Yun during the delegation period [6][17]. Group 4: Future Implications - If the share transfer and voting rights delegation are successfully completed, Chen Yun will become the controlling shareholder, replacing Tan Guoying as the actual controller of the company [6][12][17]. - The transaction aims to introduce a professional investor who recognizes the company's value and future prospects, thereby supporting the company's high-quality development [18].

本次协议转让完成后，公司控股股东将由李光平、王春晓、李羿含变更为交投资本，公司实际控制人将 由李光平、王春晓、李羿含变更为湖北省国资委。因控股股东、实际控制人筹划重大事项已取得重大进 展,公司股票将于12月1日复牌。 公告显示，本次交易转让价格为每股41.16元，转让价款总额为7.7亿元。超卓航科停牌前股价51.45元。 本次股份转让完成后，湖北交投资本的累计持股将占公司总股本的20.93%，李光平仍持有公司11.82% 的股份，李羿含仍持有公司17.01%的股份。 来源：上海证券报·中国证券网 上证报中国证券网讯（记者 丁鹏）11月28日晚，超卓航科发布公告称，公司控股股东、实际控制人李 光平、王春晓、李羿含当天与湖北交投资本投资有限公司（简称"湖北交投资本"）签署了股份转让协 议，李光平、王春晓、李羿含将其合计持有的公司1875.8万股股票（占公司目前总股本的20.93%，简 称"标的股份"）协议转让给湖北交投资本。 因此，在公司控制权变更后，李光平、王春晓、李羿含实际拥有的表决权占比为11.82%，湖北交投资 本拥有的表决权占比为20.93%。 超卓航科表示，公司当前股权结构及现有业务体量难以支撑行业快 ...